In vivo programming of endogenous antibodies via oral administration of adaptor ligands
摘要:
Vaccination is a reliable method of prophylaxis and a crucial measure for public health. However, the majority of vaccines cannot be administered orally due to their degradation in the harsh gut environment or inability to cross the GI tract. In this study, we report the first proof-of-concept study of orally producible chemically programmed antibodies via specific conjugation of adaptor ligands to endogenous antibodies, in vivo. Pre-immuniztion with 2,4-dinitrophenyl (DNP), or the reactive hapten, 1,3-diketone (DK), or a novel reactive hapten, vinyl sulfone (VS) in mice, followed by oral administration of adaptor ligands composed of the hapten and biotin to the pre-immunized mice resulted in successful in vivo formation of the biotin-hapten-antibody complexes within 2 h. Pharmacokinetic evaluations revealed that apparent serum concentrations of programmed antibodies were up to 144 nM and that the serum half-lives reached up to 34.4 h. These findings show promise for the future development of orally bioavailable drug-hapten-antibody complexes as a strategy to quickly and easily modulate immune targets for aggressive pathogens as well as cancer. (C) 2017 Elsevier Ltd. All rights reserved.
Efficient synthesis of diverse heterobifunctionalized clickable oligo(ethylene glycol) linkers: potential applications in bioconjugation and targeted drug delivery
Systematic Potency and Property Assessment of VHL Ligands and Implications on PROTAC Design
作者:Johannes Krieger、Fiona J. Sorrell、Ansgar A. Wegener、Birgitta Leuthner、Fouzia Machrouhi‐Porcher、Martin Hecht、Eva M. Leibrock、Juliane E. Müller、Jonathan Eisert、Ingo V. Hartung、Sarah Schlesiger
DOI:10.1002/cmdc.202200615
日期:——
Our study describes a systematic evaluation of structure-activity-relationships and structure-property-relationships for VHLligand designs. With a particular focus on exit vector analysis, we used our gained knowledge to design a small library of highly potent BRD4-PROTACs with favorable molecular properties and improved degradation potency compared to MZ1.